One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration

Eye (Basingstoke)

Volumn 31, Issue 6, 2017, Pages 878-883

  Almuhtaseb, H ^a,b   Kanavati, S ^a   Rufai, S R ^a,b   Lotery, A J ^a,b  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; HYBRID PROTEIN; VASCULOTROPIN RECEPTOR;

AGE RELATED MACULAR DEGENERATION; ARTICLE; BEST CORRECTED VISUAL ACUITY; CENTRAL RETINAL THICKNESS; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OPTICAL COHERENCE TOMOGRAPHY; RETINA MACULA HEMORRHAGE; SUBRETINAL FLUID; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; EYE FUNDUS; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MALE; PATHOLOGY; PATHOPHYSIOLOGY; RETINA; RETROSPECTIVE STUDY; VERY ELDERLY; VISUAL ACUITY; WET MACULAR DEGENERATION;

AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; INTRAVITREAL INJECTIONS; MALE; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINA; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 85020412016     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2017.6     Document Type: Article

References (11)

1. Owen C, Jarrar Z, Wormald R, Cook DG, Fletcher AE, Rudnicka AR. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol 2012; 96(5): 752-756.
2. Rudge JS, Ioffe E, Cao J, Papadopoulos N, Thurston G, Wiegand SJ et al. Clincal development of VEGF trap biology of VEGF and its receptors. In: Figg WD, Folkman J (eds). Angiogenesis. Springer: New York, NY, USA, 2008, pp 415-420.
3. Heier JS, Brown DM, Chong V, Korobelnik J-F, Kaiser PK, Nguyen QD et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012; 119(12): 2537-2548.
4. Schmidt-Erfurth U, Kaiser PK, Korobelnik J-F, Brown DM, Chong V, Nguyen QD et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety six-week results of the VIEW studies. Ophthalmology 2014; 121(1): 193-201.
5. Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group. The neovascular agerelated macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. Ophthalmology 2014; 121: 1092-1101.
6. Talks JS, Lotery AJ, Ghanchi F, Sivaprasad S, Johnston RL, Patel N et al. United Kingdom Aflibercept Users Group. First-year visual acuity outcomes of providing aflibercept according to the VIEW study protocol for age-related macular degeneration. Ophthalmology 2016; 123(2): 337-343.
7. Wykoff CC, Croft DE, Brown DM, Wang R, Payne JF, Clark L et al. Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology 2015; 122(12): 2514-2522.
8. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W et al. Variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009; 148(1): 43-58.
9. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR Study. Ophthalmology 2009; 116(1): 57-65.
10. NICE, aflibercept price. Available at: https://www. evidence.nhs.uk/formulary/bnf/current/8-malignantdisease-and-immunosuppression/81-cytotoxic-drugs/815-other-antineoplastic-drugs/aflibercept/aflibercept#Search? q=aflibercept price (6 February 2017).
11. NICE, Lucentis® (Novartis). Available at: https://www. evidence.nhs.uk/formulary/bnf/current/11-eye/118-miscellaneous-ophthalmic-preparations/1182-ocular-diagnosticand-peri-operative-preparations-and-photodynamic-treatment/ subfoveal-choroidal-neovascularisation/ranibizumab/lucentis (6 February 2017).